Image

Global Bevacizumab Market - Industry Trends and Forecast to 2028

  • Pharmaceutical
  • Upcoming Report
  • Jan 2021
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Jan 2021
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Bevacizumab Market, By Diseases (Cancer, Eye Disorder), Brand Name (Avastin, Mvasi, Zirabev, Versavo), Dosage (100mg, 400mg), Application (Non Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, Cervical Cancer, Colorectal Cell Cancer, Ovarian Cancer, Proliferative Diabetic Retinopathy, Malignant Glioma, Neurofibromatosis, Pancreatic Cancer, Others), End-Users (Hospitals, Cancer Supportive Centres, Home Healthcare, Academic and Research Institutes, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028

Bevacizumab Market Market Analysis and Insights: Global Bevacizumab Market

The bevacizumab market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 9.20% in the above-mentioned research forecast period. The factors responsible for the growth of the demand for bevacizumab are emerging markets and massive investments in research and development.

Bevacizumab is a humanized recombinant monoclonal antibody which is effective against vascular endothelial growth factor called VEGF (pro angiogenic cytokine) which is made up of cells that help in new blood vessel formation. Bevacizumab acts by binding to VEGF and subsequently inhibiting its receptor binding process which prevents growth of tumour and cancerous cells. Bevacizumab is currently undergoing many trials for being used in combinations with other drugs for cancer treatment.

Increasing prevalence of cancer and changing lifestyle along with support groups are being instrumental for cancer patients in coping with cancer by providing funds and supportive care will boost up the bevacizumab market growth, emerging market and collaboration of global pharmaceutical manufacturers also have a positive impact on the global bevacizumab market. As per a study, the use of bevacizumab is more cost effective when compared to other drugs of similar category which would motivate the bevacizumab market growth, meanwhile, the patent in the U.S. for bevacizumab biosimilar expired in year 2019 and European patent for the same will expire in year 2022 giving manufacturers a chance to enter the global bevacizumab market which would be a market booster. The numerous drug interactions and adverse effects associated with the bevacizumab treatment along with high risk of resistance in patients may have a negative impact on the bevacizumab market. Adding up to the same, during clinical trials the drug showed no survival difference amongst the clinical trial subjects when compared to traditional chemotherapy. The dominance of other alternative medications which are comparatively expensive in country namely the U.K. may affect the bevacizumab market growth in that region.  

Drug manufacturer Roche received an approval for ophthalmic off label use of bevacizumab which will create opportunities for the bevacizumab market, whereas FDA expanded its approval for use of olaparib in combination with bevacizumab for maintenance therapy in adult patients suffering from advanced epithelial ovarian, primary peritoneal cancer which will boost the bevacizumab market. Rising awareness about cancer is an opportunity for the associated bevacizumab market to prosper. Increasing demand of targeted therapy along with price cuts will boost the growth of global bevacizumab market. However, the global bevacizumab market also has certain challenges such as in the United States, insurance companies refuse to include bevacizumab biosimilar avastin therapy. Its reimbursement is also restricted in Canada due to its low benefit to cost ratio. Unavailability of any generic form of bevacizumab in the market due to current regulations governing its manufacturing is a challenge. Bevacizumab patent holders are working on secondary patent strategies which would complicate the manufacturing of bevacizumab biosimilars which would have impact on the bevacizumab market.

This bevacizumab market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the bevacizumab market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Bevacizumab Market Scope and Market Size

The bevacizumab market is segmented on the basis of diseases, brand name, dosage, application, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of diseases, the bevacizumab market is segmented into cancer and eye disorder.
  • On the basis of brand name, the bevacizumab market is segmented into avastin, mvasi, zirabev and others.
  • On the basis of dosage, the bevacizumab market is segmented into 100mg and 400mg
  • On the basis of application, the bevacizumab market is segmented into non squamous non-small cell lung cancer, recurrent glioblastoma, cervical cancer, colorectal cell cancer, ovarian cancer, proliferative diabetic retinopathy, malignant glioma, neurofibromatosis, pancreatic cancer and others.
  • On the basis of end-users, the bevacizumab market is segmented into hospitals, cancer supportive centres, home healthcare, academic and research institutes and others.
  • On the basis of distribution channel, the bevacizumab market has also been segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others.

Global Bevacizumab Market Country Level Analysis

Global bevacizumab market is analysed and market size information is provided by country, diseases, brand name, dosage, application, end-users and distribution channel as referenced above.

The countries covered in the bevacizumab market report are the U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

On geographical estimation, Europe accounts for the largest market share due to the increased consumption of bevacizumab for the treatment of various types of cancer. Asia-Pacific is expected to account for the largest market share over coming years for the bevacizumab market due to increasing prevalence and growing healthcare expenditure.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The bevacizumab market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to bevacizumab market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the bevacizumab market in the growth period. 

Competitive Landscape and Bevacizumab Market Share Analysis

The bevacizumab market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to bevacizumab market.

The major players covered in the bevacizumab market are Genentech, Amgen, Pfizer Inc., Allergan, Biocon, Reliance Life Sciences, Beacon Pharmaceuticals Limited, Celgene Corporation, Mylan Inc, Dr. Reddy’s Laboratories Ltd, Eli Lilly and Company, BioXpress Therapeutics, Teva Pharmaceutical industries Ltd., CELLTRION INC., mAbxience, Samsung Bioepis, FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., Hetero Drugs, AryoGen Pharmed and Zydus Cadila among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Pfizer Inc. has received approval from the U.S. FDA for zirabev which is a bevacizumab biosimilar for treatment of five types of cancer namely metastatic colorectal cancer, unresectable, locally advanced recurrent or metastatic non squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma and persistent, recurrent or metastatic cervical cancer. This will increase the market competition.


SKU-

Why Choose Us


Frequently Asked Questions